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Abstract
Background:  While gelatinase (MMP-2 and -9) activity is increased after focal ischemia/
reperfusion injury in the brain, the relative contribution of neutrophils to the MMP activity and to
the development of hemorrhagic transformation remains unknown.
Results: Anti-PMN treatment caused successful depletion of neutrophils in treated animals. There
was no difference in either infarct volume or hemorrhage between control and PMN depleted
animals. While there were significant increases in gelatinase (MMP-2 and MMP-9) expression and
activity and edema formation associated with ischemia, neutrophil depletion failed to cause any
change.
Conclusion: The main finding of this study is that, in the absence of circulating neutrophils, MMP-
2 and MMP-9 expression and activity are still up-regulated following focal cerebral ischemia.
Additionally, neutrophil depletion had no influence on indicators of ischemic brain damage including
edema, hemorrhage, and infarct size. These findings indicate that, at least acutely, neutrophils are
not a significant contributor of gelatinase activity associated with acute neurovascular damage after
stroke.
Background
The matrix metalloproteinases (MMPs) are a family of
some 23 zinc dependent proteases that, collectively, pos-
sess the ability to degrade nearly every component of the
extra-cellular matrix [1-3]. The activity of the MMPs is
tightly controlled through proteolytic activation of the
zymogen forms and stoichiometric binding of tissue
inhibitors of metalloproteinases (TIMPs). The MMPs play
an important role in many physiological processes due to
their inherent ability to remodel tissues [2,3]. However, in
disease states such as vascular disease and stroke, the
MMPs may become deleterious due to dysregulation and
can result in tissue injury and inflammation. Specifically,
the MMPs may be involved in the degradation of the basal
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lamina in reperfusion injury resulting in disruption of the
blood brain barrier and hemorrhagic transformation [4].
Recently, several lines of evidence have demonstrated the
involvement of the MMPs in cerebral ischemia. Studies in
rat, mouse, and baboon models have shown that MMP-9
is up-regulated following transient focal ischemia [5-8].
Additionally, Asahi et al. have shown that MMP-9 knock-
out as well as MMP-9 inhibition reduces ischemic lesion
volume [9]. However, others have shown that pharmaco-
logical inhibition of MMP-9 yields no change [10,11].
Lapchak et al. demonstrated that broad-spectrum MMP
inhibition (BB-94) reduced the incidence of hemorrhage
in tPA treated brains when administered shortly after the
onset of ischemia [11]. In addition, Sumii et al. were able
to show a reduction in hemorrhage severity in tPA treated
animals given the same MMP inhibitor BB-94 [10].
Clearly the MMPs are involved in the pathology of cere-
bral ischemia and hemorrhagic transformation. However,
there is still uncertainty as to the origin of MMP activity.
Immunohistochemical studies from Asahi et al. demon-
strated that MMP-9 is primarily up-regulated in the vascu-
lar spaces while others have shown that there is a
concomitant staining of neutrophils in the areas of MMP-
9 activation suggesting a role for the neutrophil in the up-
regulation of MMP-9 [12-14]. Indeed, a recent study has
shown that prevention of neutrophil infiltration signifi-
cantly reduces MMP-9 up-regulation in an occlusion/
reperfusion model of ischemia [15]. The source of MMP
activity in focal cerebral ischemia is important to the
development of therapies to target this mediator of neu-
rovascular injury. It is still unknown whether neutrophils
are an important source of MMPs in experimental hemor-
rhagic transformation.
The objective of the current study was to evaluate the role
of the neutrophil in hemorrhagic transformation and
edema formation in a hyperacute 3-hour occlusion/reper-
fusion model of focal ischemia. The central hypothesis
was that depletion of neutrophils would reduce hemor-




Control and neutrophil-depletion groups received normal
rabbit serum and anti-PMN antibody, respectively, 24
hours prior to middle cerebral artery occlusion (MCAO)
surgery. The dose of the anti-neutrophil antibody chosen
(and this was batch-specific in our preliminary studies –
not shown) was very effective in reducing the circulating
neutrophils. In control animals that received normal
serum, neutrophil count, expressed as mean ± SE of per-
cent of total leukocyte count, was 11.8 ± 0.92% and as
expected did not differ from baseline. In the depletion
group, administration of anti-PMN antibody reduced the
neutrophil count to 0.3 ± 0.11% from 9.4% at baseline (p
< 0.0001 compared to serum). All animals included in the
neutropenic group had >90% depletion of their neu-
trophils prior to the stroke surgery, as assessed by a
blinded investigator using a hemocytometer (Fig. 1). The
body weight of control animals was 288 ± 4 g at baseline,
292 ± 4 g prior to stroke and 237 ± 4 g at 24 hours. In the
antibody-treated group, body weight was 300 ± 4 g at
baseline, 292 ± 5 prior to stroke surgery, and 240 ± 5 g at
24 hours.
Gelatinase quantification
Ischemia for three hours followed by 24 h reperfusion
resulted in a significant increase in the expression and
activity of both MMP-2 and MMP-9 in the ipsilateral hem-
ispheres (Fig. 2). Quantitative analysis of the gelatin
zymography revealed consistent increases in the lower
molecular weight form of MMP-9 (88 kDa). Although
there was a faint band corresponding to 95 kDa MMP, the
gelatinolytic activity in control vs neutrophil-depleted
animals was similar. Protein levels of MMP-2 (Fig. 3) and
MMP-9 (Fig. 4) were significantly increased in the
ischemic hemisphere and neutrophil depletion did not
affect MMP protein levels.
Neutrophil counts at baseline and at 24 hours after normal  rabbit serum (control) or anti-PMN antibody (PMN- depleted) administration Figure 1
Neutrophil counts at baseline and at 24 hours after normal 
rabbit serum (control) or anti-PMN antibody (PMN-
depleted) administration. Anti-PMN antibody resulted in a 
consistent decrease in circulating neutrophils to less than 
10% of baseline counts whereas there was no change in neu-
trophil counts in control animals that received the normal 
rabbit serum. *p < 0.001 control (n = 8) vs after PMN-deple-
tion (n = 10).BMC Neuroscience 2005, 6:49 http://www.biomedcentral.com/1471-2202/6/49
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MMP activity is increased in focal cerebral ischemia Figure 2
MMP activity is increased in focal cerebral ischemia. (A) Representative zymogram showing changes in MMP activity in the 
ischemic (I) and non-ischemic (N) hemispheres. (B) Densitometric analysis of lytic bands indicates increases in MMP-2 and 
MMP-9 activity in ischemic hemispheres from control and PMN-depleted animals. Anti-PMN antibody treatment has no affect 
on MMP activity. (*p < 0.05 vs contralateral hemisphere, control n = 6, PMN n = 4).BMC Neuroscience 2005, 6:49 http://www.biomedcentral.com/1471-2202/6/49
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MMP-2 protein expression is increased in ischemia Figure 3
MMP-2 protein expression is increased in ischemia. (A). Representative immunoblot demonstrating changes in MMP-2 protein 
expression in ischemic hemispheres from control and PMN-depleted animals. (B) Densitometric analysis of immunoreactive 
bands indicates that MMP-2 protein is increased in ischemia and is unchanged by neutrophil depletion. (*p < 0.05 vs contralat-
eral hemisphere, saline n = 6, PMN n = 4).BMC Neuroscience 2005, 6:49 http://www.biomedcentral.com/1471-2202/6/49
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MMP-9 protein expression is unchanged by neutrophil depletion Figure 4
MMP-9 protein expression is unchanged by neutrophil depletion. (A). Representative immunoblot showing immunoreactive 
MMP-9 bands in both ischemic (I) and non-ischemic (N) hemispheres. (B) Densitometric analysis indicates an ischemia induced 
elevation of MMP-9 expression that is unaffected by PMN depletion. (*p < 0.05 vs contralateral hemisphere, control n = 6, 
PMN n = 4).BMC Neuroscience 2005, 6:49 http://www.biomedcentral.com/1471-2202/6/49
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Infarct size, edema and hemorrhage assessment
There was no significant effect of neutrophil depletion on
either infarct size or the development of hemorrhagic
transformation in our model (Figure 5). In addition,
cerebral edema formation was similar between untreated
and neutrophil-depleted animals. Neurologic examina-
tion at 24 hours was not significantly different between
the two treatment groups (not shown).
Discussion
Cerebral ischemia and reperfusion are known to induce
large increases in MMP-9 protein and activity in the
affected hemisphere and MMP-9 has been associated with
hemorrhage formation in humans [16] and experimental
animals [10]. Experimental inhibition of the MMPs has
been associated with decreased hemorrhage formation
and improved stroke outcome [11]. Since neutrophils are
a known source of MMP-9, this study was designed to
determine whether neutrophil depletion, prior to cerebral
artery occlusion, would decrease MMP expression and
reduce hemorrhagic transformation.
Despite the fact that neutrophil depletion was essentially
complete prior to the focal cerebral ischemia in our exper-
iment, we detected an increase in gelatinolytic activity cor-
responding to 86–88 kDa MMP-9. There was a faint band
for the 95 kDa proMMP-9, and the activity did not differ
between the ischemic and non-ischemic hemispheres.
Immunoblotting experiments confirmed the results of
gelatin zymography and showed that specific up-regula-
tion of the MMP-9 protein is responsible for increased
gelatinolytic activity. Justicia et al. reported that, in a 1 h
MCAO model in which the neutrophil depletion or antag-
onism was achieved by vinblastine administration or neu-
tralizing antibodies against VCAM-1, respectively, there
was no effect on the 88 kDa MMP-9 expression but,
increases in 95 kDa MMP-9 activity were prevented. Our
results are in agreement with this observation that neu-
trophils are not the source of 88 kDa MMP-9. However,
we do not detect any increase in 95 kDa MMP-9. This dif-
ference may be due to the duration of ischemia (1 h vs 3
h) and the extent of ischemic damage [15]. We have pre-
viously shown that hemorrhagic transformation occurs in
various different regions of the injured hemisphere
including: preoptic area, striatum and the lateral cortex in
this model and that development of hemorrhagic trans-
formation is related to the duration of occlusion, with no
hemorrhage when reperfusion occurs after only 1 hour
[17,18].
In this model of focal cerebral ischemia and hemorrhagic
transformation, where the MCA was occluded for 3 hours
prior to reperfusion, no significant effect of neutrophil
depletion could be shown on either neurovascular dam-
age or neurologic function. Also, from our results, it is
clear that neutrophils are not an important contribution
to the increased MMP-9 expression in the 24 hours after
this injury. It is possible that the contributions of neu-
trophils are greater when the injury to the brain is less pro-
found than in our model. Several different investigators
have demonstrated that preventing the adhesion of neu-
trophils [19] after ischemia and reperfusion reduces the
ultimate injury. Maier et al. reported that in superoxide
dismutase (SOD) knock-out animals that are more sus-
ceptible to ischemic damage, neutrophils are not the
source of MMP-9 contributing to blood brain barrier
breakdown providing further support for the results of
this present study [20].
Activated neutrophils release free radicals and proteolytic
enzymes such as MMP-8 (neutrophil elastase), in addition
to activating cytokines, which further the recruitment of
leukocytes to the site of injury. We initially thought that
neutrophil adherence and activation may be an early con-
tributor to the development of microvascular injury and
hemorrhagic transformation after cerebral ischemia but
this turned out to be not the case [21]. It is still possible
that neutrophils are involved in the destruction of the
basal lamina, but it is likely to occur later in the process,
after neutrophil recruitment is maximal.
Conclusion
Although neutrophils have been shown to contain MMP-
9, release of MMP-9 by neutrophils is probably not the
mechanism of the early microvascular damage leading to
edema formation and hemorrhagic transformation in our
model. In addition, neutrophil adhesion is not necessary
for the increase in activation of MMP-9 after ischemia.
Although neutrophils may contribute to the ultimate
degree of neurologic damage after ischemia and reper-
fusion in the brain, they are not necessary for the develop-
ment of hemorrhagic transformation.
Methods
Neutrophil depletion
Neutrophil depletion was accomplished by intravenous
administration of a polyclonal rabbit anti-rat polymor-
phonuclear neutrophil (PMN) antiserum (Accurate
Chemical and Scientific Corporation, Westbury, NY) 24
hours prior to ischemia [22]. Animals were randomized to
receive either the PMN antiserum (0.3 mL diluted in 1 mL
saline) or an equal volume of normal rabbit serum (con-
trol) 24 hours prior to surgery. Neutrophil counts, as a
percentage of total leukocyte count, were determined at
baseline and 23 hours post administration to determine
the level of depletion.
Animal preparation/physiological monitoring
The Care of Experimental Animal Committee of Medical
College of Georgia approved the protocol. Male WistarBMC Neuroscience 2005, 6:49 http://www.biomedcentral.com/1471-2202/6/49
Page 7 of 9
(page number not for citation purposes)
Infarct size, edema formation and hemoglobin excess differences between control and PMN-depleted animals Figure 5
Infarct size, edema formation and hemoglobin excess differences between control and PMN-depleted animals. (A). Infarct size, 
as measured by TTC staining, indicated no differences between depletion and control groups. (B). Likewise, PMN depletion 
had no affect on the development of hemorrhagic transformation. (C) Edema determined as the difference in area between the 
ischemic and non-ischemic hemispheres was similar in neutrophil-depleted and control animals (n = 8 control, n = 10 PMN).BMC Neuroscience 2005, 6:49 http://www.biomedcentral.com/1471-2202/6/49
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rats, from the Charles River Breeding Company (Wilming-
ton, MA, USA) within a narrow range of body weight
(250–300 g) were used. All animals were anesthetized
with 2% isoflurane via inhalation. Cerebral ischemia was
induced using the intraluminal suture MCAO model [23].
The MCA was occluded with a 19–21 mm 4-0 surgical
nylon filament, which was introduced from the external
carotid artery lumen into the internal carotid artery to
block the origin of the MCA. The suture was removed after
3 hours of occlusion. We have shown previously that
hemorrhagic transformation is related to the duration of
occlusion in this model [17,18]. Prior to, and after reper-
fusion, each rat was evaluated neurologically using the
Bederson Scale [24]. After 21 hours of reperfusion, the
animals were anesthetized with ketamine 44 mg/kg and
xylazine 13 mg/kg I.M. (cocktail), perfused with saline,
sacrificed, and the brain tissue was removed.
Brain preparation and homogenization
The brains were sliced into seven 2-mm thick slices in the
coronal plane and stained with a 2% solution of 2, 3, 5-
triphenyltetrazolium chloride (TTC) (Sigma Chemical
Co., USA) for 15–20 minutes. Images of the stained sec-
tions were taken. Grossly visible infarction zones were
quantified using image analysis software (Zeiss- KS 300)
in pixel2 [25]. Because brain edema can affect the accuracy
of infarct assessment [26], the measurement of the cor-
rected infarct size was taken [27,28]. The ischemic and
non-ischemic hemispheres of the slices for the ELISA
assay were separated and processed individually, using the
non-ischemic side as a control. Each slice was homoge-
nized, vortexed and sonicated. Quantification of the
hemoglobin was accomplished using a direct ELISA
method, as previously described [29].
For zymography and western blotting, brains were placed
in a chilled coronal matrix and 2-mm sections were
removed from the core of the infarct. The slices were col-
lectively placed, by hemisphere, into labeled tubes, flash
frozen, and stored at -80°C until use. Samples were
homogenized according to the methods of Heo et al. [7].
Briefly, samples were placed in 300 µL cold working
buffer consisting of 50 mmol/L Tris-HCl (pH 7.5), 75
mmol/L NaCl, and 1 mmol/L PMSF, homogenized with a
glass homogenizer and centrifuged at 4°C for 20 minutes
at 9000 rpm. The supernatant was collected and stored at
-80°C until use. Protein concentrations were determined
using the Bradford method.
Gelatin zymography
On the day of the experiment, samples (20 µg protein/
sample) were loaded onto 10% gelatin zymogram gels
(Bio-Rad) and separated under nonreducing conditions
[30]. The gels were then rinsed twice in 2.5% Triton X-100
and incubated for 24 hours in substrate buffer containing
21 mM Tris·HCl, 10 mM CaCl2, 0.04% NaN3. Gels were
then stained by Coomassie blue R-250 followed by
destaining in 55% methanol and 7% acetic acid. Lytic
activity was viewed as clear bands on a dark blue back-
ground and was quantitated by densitometric analysis
(Gel-Pro v 3.1, Media Cybernetics, Carlsbad, CA.).
Edema quantitation
Brain edema was measured as a difference in area between
the ischemic and non-ischemic hemispheres. The brain
section analyzed was the one corresponding to the area of
the ischemic damage in four consecutive 2-mm slides. The
brain slides were analyzed separately and the areas and
differences combined for whole hemi-section compari-
son. The area analysis was done using Zeiss KS-300.
Statistics
A Wilcoxon rank sum test was performed to make group
comparisons (control vs. depletion) in MMP activity and
protein expression for the difference between the ischemic
and non-ischemic sides of the brain and group compari-
sons for neutrophil depletion, edema, infarct size and
hemorrhagic transformation. A Wilcoxon signed rank test
was used to make within rat comparisons between
ischemic and non-ischemic sides of the brain for MMP
activity and protein expression. Statistical significance was
determined at p < 0.05 and SAS 8.2 was used for all
analyses.
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